Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
FIBROGEN INC (FGEN)
|
Add to portfolio |
|
|
|
| Price: |
$14.82
| | Metrics |
| OS: |
98.2
|
M
| |
|
|
| Market cap: |
$1.46
|
B
| |
-185
|
% ROIC
|
|
Net cash:
|
$81.2
|
M
| |
$0.83
|
per share
|
|
EV:
|
$1.37
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($326)
|
M
| |
|
|
| EPS |
($2.52)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 140.7 | 140.7 | 235.3 | 235.3 | 176.3 | 256.6 | 213.0 | 131.0 |
| Revenue growth | -40.2% | -40.2% | 33.5% | | -31.3% | 20.5% | 62.6% | -28.5% |
| Cost of goods sold | 441.8 | 20.3 | 463.8 | 12.9 | 368.2 | 1.1 | 0.0 | 0.0 |
| Gross profit | -301.0 | 120.5 | -228.5 | 222.4 | -191.9 | 255.4 | 213.0 | 131.0 |
| Gross margin | -213.9% | 85.6% | -97.1% | 94.5% | -108.8% | 99.6% | 100.0% | 100.0% |
| Selling, general and administrative | 0.0 | 124.7 | 60.0 | 123.9 | 0.0 | 135.5 | 63.8 | 51.8 |
| Research and development | | 296.8 | | 387.0 | | 209.3 | 235.8 | 196.5 |
| EBIT | -287.3 | -301.0 | -231.8 | -288.5 | -183.2 | -89.3 | -86.7 | -117.3 |
| EBIT margin | -204.1% | -213.9% | -98.5% | -122.6% | -103.9% | -34.8% | -40.7% | -89.5% |
| Pre-tax income | -294.9 | -294.9 | -290.7 | -290.7 | -188.7 | -76.6 | -86.1 | -120.6 |
| Income taxes | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 |
| Tax rate | | | | | | | | |
| Net income | -293.7 | -293.7 | -290.0 | -290.0 | -189.3 | -77.0 | -86.4 | -120.9 |
| Net margin | -208.7% | -208.7% | -123.3% | -123.3% | -107.4% | -30.0% | -40.6% | -92.3% |
| |
| Diluted EPS | ($3.14) | ($3.14) | ($3.14) | ($3.14) | ($2.11) | ($0.89) | ($1.03) | ($1.66) |
| Shares outstanding (diluted) | 93.6 | 93.6 | 92.3 | 92.3 | 89.9 | 86.6 | 84.1 | 73.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|